Application aspects of medications for inhalation at the prehospital stage of medical evacuation

Abstract

This study aimed to determine the aspects of inhalation application of drugs as medical means of protection against lesions by factors of radiation, chemical, and biological nature at the prehospital stage of medical evacuation. Advantages of inhalation administration of drugs and use of individual inhalers of portable type over parenteral and oral administration methods are described. The existing drugs that are most suitable for inhalation at the prehospital stage of medical evacuation include emergency prevention and treatment of toxic pulmonary edema, analgesics, antiradiation, drugs for arresting radiation primary reaction, agents for accelerated radionuclides elimination, and antibacterial and antiviral agents. This list is conditioned by the rapid achievement of the protective effect of the drug during inhalation, both due to the local action in the area of the “entrance gate” of the intake of damaging agents and the accelerated absorption and systemic action on target organs. This study presents data on existing and promising inhalation drugs (antidotes for warfare agents, recombinant forms of acetyl- and butyrylcholinesterase) and technical means of their delivery (a metered aerosol inhaler, a metered dry powder inhaler) in the Armed Forces of the European North Atlantic Treaty Organization bloc and the United States for the prevention and treatment of damage e to chemical agents, as well as the prospects of radiomitigator usage (granulocyte-macrophage colony-stimulating factor) by inhalations for acute radiation syndrome treatment and inhalation of complexones of radioactive isotopes. The prospects of inhalation in combination with bronchodilators in the development of acute respiratory failure and toxic pulmonary edema on the background of poisoning with the use of a metered-dose powder inhaler are described. The introduction and use of a metered-dose dry powder inhaler at the prehospital stage of medical evacuation determines the need for its development, taking into account the specifics of the drug usage, as well as the need to unify the dosage form of drugs in combination with one type of inhaler (single-dose or multi-dose).

Keywords

antidotes / metered-dose powder inhaler / pulmonary toxicants / radiomitigators / poisonous substance involvement / prehospital stage of medical evacuation / complexes of radioactive isotopes / acute radiation disease

References

[1] Blinov DV, Akarachkova ES, Orlova AS, et al. New framework for the development of clinical guidelines in Russia. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(2): 125–144. (In Russ.). DOI: 10.17749/2070-4909.2019.12.2.125-144.

[2] Блинов Д.В., Акарачкова Е.С., Орлова А.С., и др. Новая концепция разработки клинических рекомендаций в России // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2019. Т. 12, № 2. С. 125–144. DOI: 10.17749/2070-4909.2019.12.2.125-144

[3] Department of the Army, Marine Corps Combat Development Command, Navy Warfare Development Command, Air Force Doctrine Center. Multiservice tactics, techniques and procedures for treatment of chemical agent casualties and conventional military chemical injuries. USA South Carolina: Create Space Independent Publishing Platform, 2012. 192 p.

[4] Corcoran TE, Venkataramanan R, Hoffman RM, et al. Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(1):46–55. DOI: 10.1089/JAMP.2011.0948

[5] Corcoran T.E., Venkataramanan R., Hoffman R.M., et al. Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler // J Aerosol Med Pulm Drug Deliv. 2013. Vol. 26, No. 1. P. 46–55. DOI: 10.1089/JAMP.2011.0948

[6] Masson P, Nachon F. Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning. J Neurochem. 2017;142(2):26–40. DOI: 10.1111/jnc.14026

[7] Masson P., Nachon F. Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning // J Neurochem 2017. Vol. 142, No. 2. Р. 26–40. DOI: 10.1111/jnc.14026

[8] Rosenberg YJ, Adams RJ, Hernandez-Abanto S, et al. Pharmacokinetics and immunogenicity of a recombinant human butyrylcholinesterase bioscavenger in macaques following intravenous and pulmonary delivery. Chem Biol Interact. 2015;(242):219–226. DOI: 10.1016/ J.CBI.2015.09.021

[9] Rosenberg, Y.J., Adams R.J., Hernandez-Abanto S., et al. Pharmacokinetics and immunogenicity of a recombinant human butyrylcholinesterase bioscavenger in macaques following intravenous and pulmonary delivery // Chem Biol Interact. 2015. No. 242. Р. 219–226. DOI: 10.1016/ J.CBI.2015.09.021

[10] Rosenberg YJ, Fink JB. Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavenger. Ann N Y Acad. Sci. 2016;1374(1):151–158. DOI: 10.1111/NYAS.13106

[11] Rosenberg Y.J., Fink J.B. Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavenger // Ann N Y Acad Sci. 2016. Vol. 1374, No. 1. Р. 151–158. DOI: 10.1111/NYAS.13106

[12] Sventitskaya АМ, Orlova AB, Subbotina SN, et al. Prospects for the use of scavengers as antidote therapy for acute poisoning with anticholinesterase substances (literature review). Medline.ru. 2020;21:452–473. (In Russ.).

[13] Свентицкая А.М., Орлова А.Б., Субботина С.Н., и др. Перспективы применения скавенджеров в качестве средств антидотной терапии острых отравлений веществами антихолинэстеразного действия (обзор литературы) // Российский биомедицинский журнал. 2020. Т. 21. С. 452–473.

[14] Rosenberg YJ, Laube B, Mao L, et al. Pulmonary delivery of an aerosolized recombinant butyrylcholinesterase pretreatment protects against aerosolized paraoxon in macaques. Chem Biol Interact. 2013;203(1):167–171. DOI: 10.1016/J.CBI.2012.11.004

[15] Rosenberg Y.J., Laube B., Mao L., et al. Pulmonary delivery of an aerosolized recombinant butyrylcholinesterase pretreatment protects against aerosolized paraoxon in macaques // Chem. Biol. Interact. 2013. Vol. 203, No. 1. Р. 167–171. DOI: 10.1016/J.CBI.2012.11.004

[16] McShane JP, Weers JG, Tarara TЕ, et al. Ciprofloxacin dry power for inhalation (ciprofloxacin DPI): technical design and features of an efficient drug-device combination. Pulm Pharmacol Ther. 2018;50:72–79. DOI: 10.1016/J.PUPT.2018.03.005

[17] McShane J.P., Weers J.G., Tarara T.Е., et al. Ciprofloxacin dry power for inhalation (ciprofloxacin DPI): technical design and features of an efficient drug-device combination // Pulm Pharmacol Ther. 2018. Vol. 50. P. 72–79. DOI: 10.1016/J.PUPT.2018.03.005

[18] Mishra M, Mishra B. Formulation optimization and characterization of spray dried microparticles for inhalation delivery of doxycycline hyclate. Yakugaku Zasshi. 2011;131:1813–1825. DOI: 10.1248/YAKUSHI.131.1813

[19] Mishra M.B. Mishra Formulation optimization and characterization of spray dried microparticles for inhalation delivery of doxycycline hyclate // Yakugaku Zasshi. 2011. Vol. 131. P. 1813–1825. DOI: 10.1248/YAKUSHI.131.1813

[20] Respaud R, Marchand D, Pelatd T, et al. Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin. J Control Release. 2016;28:21–32. DOI: 10.1016/J.JCONREL.2016.05.018

[21] Respaud R., Marchand D., Pelatd T., et al. Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin // J Control Release. 2016. Vol. 28. P. 21–32. DOI: 10.1016/J.JCONREL.2016.05.018

[22] Heslet L, Bay С, Nepper-Christensen S. Acute radiation syndrome (ARS) – treatment of the reduced host defense. Int J of General Med. 2012;(5):105–115. DOI: 10.2147/ijgm.s22177

[23] Heslet L., Bay C., Nepper-Christensen S. Acute radiation syndrome (ARS) — treatment of the reduced host defense // Int J of General Med. 2012. No. 5. P. 105–115. DOI: 10.2147/ijgm.s22177

[24] Heslet L. Trifoilium Aps, Hoersholm, assignee. Granulocyte-macrophage colony stimulating factor for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation interaction and cancer therapy. United States patent US 2014/0023612. 2014 Jan 23.

[25] Grémy O, Tsapis N, Chau Q, et al. Preferential decorporation of americium by pulmonary administration of DTPA dry powder after inhalation of aged PuO(2) containing americium in rats. Radiat Res. 2010;174(5):637–644. DOI: 10.1667/RR2203.1

[26] Grémy O., Tsapis N., Chau Q., et al. Preferential decorporation of americium by pulmonary administration of DTPA dry powder after inhalation of aged PuO(2) containing americium in rats // Radiat Res. 2010. Vol. 174, No. 5. P. 637–644. DOI: 10.1667/RR2203.1

[27] Basharin VA, Chepur SV, Tolkach PG, et al. Toksikologiya pulmonotoksikantov. Saint Petersburg; 2021. 88 p. (In Russ.).

[28] Башарин В.А., Чепур С.В., Толкач П.Г., и др. Токсикология пульмонотоксикантов. Санкт-Петербург, 2021. 88 с.

[29] Tyunin МА, Vengerovich NG, Sarana AM, et al. Min specific action of inhalation cholinolytics and 2-adrenergic agonists on external respiration in rats intoxicated with organophosphorous compounds. Toxicological Review. 2014;(2):16–21. (In Russ.).

[30] Тюнин М.А., Венгерович Н.Г., Сарана А.М., и др. Особенности действия ингаляционных холинолитиков и 2-адреномиметиков на динамику параметров внешнего дыхания у крыс при отравлении фосфорорганическими соединениями // Токсикологический вестник. 2014. № 2. С. 16–21.

[31] Chepur SV, Chubar’ ОV, Halimov YuSh, et al. Metodicheskie rekomendacii po terapii dyhatelnoy nedostatochnosti u porazhennyh otravlyayushimi i vysokotoksichnymi veshestvami na etapah medicinskoy evacuacii. Saint Petersburg; 2016. 55 p. (In Russ.).

[32] Чепур С.В., Чубарь О.В., Халимов Ю.Ш., и др. Методические рекомендации по терапии дыхательной недостаточности у пораженных отравляющими и высокотоксичными веществами на этапах медицинской эвакуации. Санкт-Петербург, 2016. 55 с.

[33] Ivanov IM, Nikiforov AS, Chepur SV, et al. Substantiation of requirements for perspective technical means of inhalational delivery of medicines for application at the stages of medical evacuation. Medline.ru. 2019;20:110–133. (In Russ.).

[34] Иванов И.М., Никифоров А.С., Чепур С.В., и др. Обоснование требований к перспективным техническим средствам ингаляционной доставки лекарственных препаратов для применения на этапах медицинской эвакуации // Российский биомедицинский журнал. 2019. T. 20. С. 110–133.

[35] Yang MY, Yan Chan JG, Chan H, et al. Pulmonary drug delivery by powder aerosols. J Control Release. 2014;193:228–240. DOI: 10.1016/J.JCONREL.2014.04.055

[36] Yang M.Y., Yan Chan J.G., Chan H., et al. Pulmonary drug delivery by powder aerosols // J Control Release. 2014. Vol. 193. P. 228–240. DOI: 10.1016/J.JCONREL.2014.04.055

[37] Zaycev AA, Okovityj SV, Kryukov EV. Kashel’. Мoscow; 2015. 59 p.

[38] Зайцев А.А., Оковитый С.В., Крюков Е.В. Кашель. Москва, 2015. 59 с.

RIGHTS & PERMISSIONS

Ivanov I.M., Ivchenko E.V., Yudin M.A., Vengerovich N.G., Nikiforov A.S., Drachev I.S., Stepanov A.V.